These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension. Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953 [TBL] [Abstract][Full Text] [Related]
3. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy. Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524 [TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194 [TBL] [Abstract][Full Text] [Related]
5. Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension. Rothman A; Cruz G; Evans WN; Restrepo H Pulm Circ; 2020; 10(1):2045894019876545. PubMed ID: 32110381 [TBL] [Abstract][Full Text] [Related]
6. Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension. Colglazier E; Stevens L; Parker C; Nawaytou HM; Amin EK; Becerra J; Steurer M; Fineman JR Pulm Circ; 2022 Oct; 12(4):e12159. PubMed ID: 36514390 [TBL] [Abstract][Full Text] [Related]
7. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M; J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry. Lachant D; Minkin R; Swisher J; Mogri M; Zolty R; Hwang S; Seaman S; Broderick M; Sahay S Pulm Pharmacol Ther; 2023 Oct; 82():102232. PubMed ID: 37451609 [TBL] [Abstract][Full Text] [Related]
10. Different efficacy of inhaled and oral medications in pulmonary hypertension. AbuHalimeh BJ; Parambil JG; Tonelli AR Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831 [TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension. Colglazier E; Ng AJ; Parker C; Nawaytou H; Fineman JR J Pediatr Pharmacol Ther; 2021; 26(5):512-516. PubMed ID: 34239406 [TBL] [Abstract][Full Text] [Related]
12. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension. Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912 [TBL] [Abstract][Full Text] [Related]
15. Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series. Blissett S; Blusztein D; Mahadevan VS Eur Heart J Case Rep; 2020 Dec; 4(6):1-7. PubMed ID: 33442633 [TBL] [Abstract][Full Text] [Related]
16. Selexipag for the treatment of pulmonary arterial hypertension. Genecand L; Wacker J; Beghetti M; Lador F Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345 [TBL] [Abstract][Full Text] [Related]
17. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis. Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. Song C; Kunovszki P; Beaudet A J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882 [No Abstract] [Full Text] [Related]
19. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series. Fanous SM; Janmohamed M Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721 [TBL] [Abstract][Full Text] [Related]
20. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension. Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]